Tucatinib + trastuzumab + capecitabine (HER2+ metastatic ≥3L, especially with brain metastases)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TUCATINIB DRUG-TRASTUZUMAB DRUG-CAPECITABINE-BREAST |
|---|
| ID | REG-TUCATINIB-TRASTUZUMAB-CAPECITABINE-BREAST |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-HER2CLIMB-MURTHY-2019 SRC-NCCN-BREAST-2025 |
Notes
HER2CLIMB: brain-mets cohort CNS-PFS 9.9 vs 4.2 mo (HR 0.32); intracranial ORR 47% vs 20%. Established as preferred regimen for HER2+ metastatic with brain metastases (active or stable). Outside CNS-mets context, T-DXd preferred 2L (DESTINY-Breast03). Diarrhea management dominant clinical workflow burden — patient counseling + immediate loperamide access critical.
Used By
Handbook Chapters
HB-BREAST-HER2-POS-MET-1L- HER2+ metastatic breast cancer: first-line reasoning
Indication
IND-BREAST-HER2-POS-3L-TUCATINIB- IND-BREAST-HER2-POS-3L-TUCATINIB